Acrivon Therapeutics financials
$2.08+0.97%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$18.7M | -$19.9M | -$20.1M | -$19.7M | -$22.6M | -$21.7M | -$25.0M | -$25.1M | -$21.4M | -$17.7M | -$21.1M | -$16.1M |
| Net income | -$18.0M | -$19.0M | -$19.0M | -$18.2M | -$21.0M | -$19.7M | -$22.8M | -$22.4M | -$18.8M | -$16.5M | -$19.3M | -$14.5M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.43 | $-0.49 | $-0.49 | $-0.47 | $-0.55 | $-0.51 | $-0.60 | $-0.59 | $-0.52 | $-0.73 | $-0.86 | $-0.66 |
| EBITDA | -$18.3M | -$19.5M | -$19.8M | -$19.3M | -$22.3M | -$21.4M | -$24.7M | -$24.9M | -$21.2M | -$17.4M | -$20.9M | -$16.0M |
| Operating cash flow | -$14.9M | -$20.5M | -$15.2M | -$12.3M | -$16.6M | -$19.5M | -$17.4M | -$17.3M | -$13.9M | -$17.1M | -$12.4M | -$9.8M |
| Free cash flow | -$14.9M | -$20.6M | -$15.5M | -$13.2M | -$17.1M | -$19.6M | -$18.2M | -$18.3M | -$14.0M | -$17.9M | -$13.5M | -$9.8M |
| Diluted shares | 41.8M | 38.7M | 38.7M | 38.6M | 38.5M | 38.4M | 38.3M | 38.1M | 36.1M | 22.6M | 22.3M | 22.1M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $41.4M | $34.1M | $41.5M | $35.4M | $41.9M | $39.2M |
| Short-term investments | $48.5M | $63.7M | $77.1M | $93.8M | $95.5M | $110.5M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $99.1M | $107.8M | $129.7M | $145.3M | $158.6M | $176.3M |
| Total liabilities | $12.4M | $12.3M | $17.2M | $16.7M | $15.5M | $16.0M |
| Shareholders' equity | $86.7M | $95.5M | $112.5M | $128.6M | $143.0M | $160.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology